The dataset used in this study is held securely in coded format at ICES. ICES is a prescribed entity under section 45 of Ontario's Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information, without consent, for the purpose of analysis of compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Legal restrictions and data sharing agreements prohibit ICES from making the dataset publicly available. Access may be granted to those who meet the conditions for confidential access, available at <https://www.ices.on.ca/DAS>. CM holds an appointment as an ICES Scientist, which enabled access to ICES data. Data access is available to external public sector researchers either through collaboration with an ICES scientist or directly, following project approval, via a secure online desktop infrastructure (see above link for details).

Introduction {#sec006}
============

Health service access and utilization are known to vary substantially with sociodemographic factors such as sex, race, immigrant status, and income level \[[@pone.0234876.ref001]--[@pone.0234876.ref004]\]. Disparities in health service utilization are reflected in divergent experiences of the health care system and outcomes \[[@pone.0234876.ref001],[@pone.0234876.ref005]\]. However, health service utilization patterns have been less extensively described in the context of neurologic diseases, although one American study found that blacks were more likely to be hospitalized, and less likely to experience an ambulatory neurology visit, than whites \[[@pone.0234876.ref006]\]. Health service utilization patterns may be particularly relevant for multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS) and one of the primary causes of disability in young adults \[[@pone.0234876.ref007]\]. The complex treatment landscape for MS today requires specialized neurology care and early implementation of disease-modifying therapy (DMT) to promote better long-term outcomes \[[@pone.0234876.ref007],[@pone.0234876.ref008]\]. Little is known about which sociodemographic factors predict favourable health service utilization in people living with multiple sclerosis (MS). In a previous scoping review of the literature, non-white race was associated with worse access to health services for people with MS, although only 3 of 36 included studies were cohort studies \[[@pone.0234876.ref009]\].

A favourable pattern of health system utilization in those with established MS diagnoses would be characterized by regular outpatient neurology visits, as comprehensive MS care requires periodic monitoring of the patient's symptoms, neurologic examination, MRI, and response to DMT. Most MS attacks can be managed on an outpatient basis when there is consistent access to a neurologist; hence fewer emergency department visits and hospitalizations would be expected under favourable conditions \[[@pone.0234876.ref010]\]. However, the initial symptoms or attack in MS may involve an emergency department visit to facilitate diagnostic work-up and possible treatment with corticosteroids \[[@pone.0234876.ref011]\]. Hospitalization is usually required only for more severe attacks, the risk of which is reduced by DMT \[[@pone.0234876.ref010]\]. Regular primary care visits may be appropriate if they complement rather than substitute for specialty neurology care and should be interpreted in that context \[[@pone.0234876.ref012]\].

There has been no previous study of the effect of immigrant status on health service utilization among people with MS, which is the focus of this study. The effect of immigrant status on health service utilization is distinct from the question of race, as health system literacy, language, and cultural factors affect immigrants' interaction with the health care system \[[@pone.0234876.ref013]\]. We conducted this study in Ontario, Canada, a region that provides an ideal environment for isolating the effect of immigrant status beyond health coverage as it has one of the largest and most diverse immigrant populations globally \[[@pone.0234876.ref014]\]; and because residents of Ontario have access to universal health insurance without user fees. In a previous large, community-based study, immigrants reported less favourable access to health services compared to native-born individuals in both Canada and the United States, although immigrants in Canada fared relatively better than their American counterparts \[[@pone.0234876.ref001]\].

We aimed to compare health services utilization in immigrants versus long-term residents with incident multiple sclerosis (MS) in Ontario, Canada. We focused on utilization before, during, and after the MS diagnostic year. Identifying disparities in health service utilization in immigrants can lead to better understanding of inequities in health care outcomes and strategies to mitigate these disparities.

Methods {#sec007}
=======

Setting {#sec008}
-------

This retrospective cohort study was performed in the province of Ontario, Canada, using linked health administrative data. At more than 14 million residents, Ontario is the province with the largest population in Canada, and is home to the largest contingent of immigrants in Canada \[[@pone.0234876.ref015]\]. Billings and administrative data are collected through OHIP (the Ontario Health Insurance Plan), which is a universal, publicly funded program that covers both in-patient and out-patient physician and hospital services without user fees.

Data sources {#sec009}
------------

The following datasets were linked by unique encoded identifiers and analyzed at ICES. The National Ambulatory Care Reporting System (NACRS) in Ontario captures emergency department (ED) visits, including visit date and the reason for visit, which is reported using International Classification of Disease 10^th^ revision Canadian enhancement (ICD 10-CA) codes. The Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) provides data on hospitalizations including dates of admission and discharge as well as diagnoses recorded using ICD-10-CA codes. We obtained demographic information from the Registered Persons Database (RPDB) of Ontario, including age, sex, health insurance eligibility, postal code of residence (used to derive neighbourhood income quintile and urban/rural residence), and death information. Outpatient physician visits were determined from physician billing claims from OHIP. Immigrant data were obtained through the electronic Permanent Resident Database of Immigration, Refugees and Citizenship Canada (IRCC), as detailed below.

Study populations {#sec010}
-----------------

### Immigrants {#sec011}

The electronic IRCC data captures all immigrants arriving in Canada since 1985. Immigrant data have been linked with OHIP data using probabilistic matching \[[@pone.0234876.ref014]\] and with the RPDB. We thus identified immigrants arriving in Ontario since 1985. Long-term residents were defined as individuals born in Ontario or whose first date of residence in Ontario occurred before 1985. The same approach was used in several previous studies of immigrants in Ontario \[[@pone.0234876.ref014],[@pone.0234876.ref016]\].

### MS cases {#sec012}

Cases of MS were identified using a validated algorithm applied to health administrative billing data \[[@pone.0234876.ref017]\]. Briefly, the algorithm required one hospitalization or at least 5 outpatient visits for MS over a two-year period using the International Classification of Disease (ICD)-9/10-CA codes 340/G35. This algorithm has a sensitivity of approximately 85% and a specificity approaching 100% \[[@pone.0234876.ref017]\]. The index date was determined by the first in-patient or out-patient contact for a demyelinating condition as indicated by ICD-9/10-CA codes, including encephalomyelitis (323/G36 or G37), optic neuritis (377/H46), or MS (340/G35), in individuals who later met the MS algorithm. For hospitalizations, both primary and secondary discharge diagnoses of MS (340/G35) were included.

The year of MS diagnosis was defined as the period from six months before until 6 months after the index date ([Fig 1](#pone.0234876.g001){ref-type="fig"}), to account for symptoms arising weeks to months in advance of the diagnostic visit. A similar approach has been used in previous studies \[[@pone.0234876.ref018],[@pone.0234876.ref019]\]. Hence, the year before MS diagnosis was defined as the year up until 6 months before the index date, and the first year following diagnosis began 6 months after the index date. The second year following diagnosis was thus defined from 1.5 years up to 2.5 years following the index date.

![Health service utilization periods relative to MS diagnosis.\
Fig 1 demonstrates the four periods of health service utilization relative to the date of MS diagnosis.](pone.0234876.g001){#pone.0234876.g001}

Cohort selection {#sec013}
----------------

Cohort selection is shown in [Fig 2](#pone.0234876.g002){ref-type="fig"}. Briefly, data collection began in 2003 because this was the first year when electronic data were available for all datasets. Incident MS cases were identified between 1 January 2003 and 31 December 2014. End of study for health service utilization data was up until 30 June 2017 to allow for 2.5 years of follow-up after the MS index date. OHIP eligibility of at least 2 years was required for cohort selection to ensure that we were identifying incident as opposed to prevalent cases. We included those who were ≥20 or ≤65 years of age at cohort entry. The lower limit on age was imposed because MS is rare in children and the algorithm for identifying MS cases in Ontario had not been validated for those \<20 years at the time this study started \[[@pone.0234876.ref020]\]. The upper limit on age was chosen because of the relative rarity of new MS diagnoses and possible misdiagnosis at age \>65 years \[[@pone.0234876.ref021]\]. Individuals who were not resident in Ontario or those who died at the time of MS diagnosis were excluded.

![Health service utilization cohort selection flowchart.\
Fig 2 illustrates selection of the study cohort of individuals diagnosed with MS.](pone.0234876.g002){#pone.0234876.g002}

Outcomes {#sec014}
--------

The number of hospital admissions per person were recorded for year before MS diagnosis, year of diagnosis, and first two years following diagnosis. The number of outpatient neurology, other specialist (e.g. surgery, obstetrics, internal medicine, psychiatry, ophthalmology) and primary care visits per year were likewise recorded. We determined whether MS (340/G35) was listed as the primary diagnosis or cause of the visit for all years except for the year before MS diagnosis and for all visit types except for outpatient neurology visits, because of the potential for conflation of different indications for neurologic consultation.

Covariates {#sec015}
----------

Covariates included MS diagnosis year (grouped as 2003--04 (reference group), 2005--09, and 2010--14), age group at MS index date (age 20--35, 36--50, and 51--65 years; the latter was the reference group), sex, neighbourhood income quintile, urban/rural residence, and comorbidity burden. Covariates were defined as previously described \[[@pone.0234876.ref022]\]. Briefly, urban residence was classified by residence in any area with a population of ≥10,000 residents. Postal code of residence was linked with the nearest year of Canadian Census data to determine urban residence and neighbourhood income quintile. Comorbidity burden was measured using ACG® System Aggregated Diagnosis Groups (ADGs) Mortality Risk Score, a weighted score which incorporates ADGs and predicts 1-year mortality \[[@pone.0234876.ref023]\]. ADGs are based on the Johns Hopkins ACG® System Ver. 10, and are determined from hospitalization and physician visit data for the two years before the index date. Region of origin was included in the descriptive baseline characteristics of the immigrant cohort and classified as Africa, the Caribbean, East Asia, Hispanic America, the Middle East, South Asia, and Western countries (the United States, Europe, Russia, and Australia).

Analysis {#sec016}
--------

Baseline characteristics of immigrants versus long-term residents at MS index date were summarized using descriptive statistics. We compared the cohorts using Student's t-tests for continuous variables and chi-square tests for categorical variables. Crude rates of number of visits per 100 person-years (with 95% confidence intervals \[CI\]) were calculated for hospitalizations, ED visits, outpatient neurology and outpatient primary care visits based on a negative binomial distribution. Hospital length of stay was reported in days. For hospital admissions and ED visits, we analyzed MS-specific and total number of visits separately. MS-specific visits were not considered in the year before diagnosis because by our cohort definitions there were no recorded MS indications at that time. We compared utilization rates between immigrants and long-term residents using rate ratios (RR) and 95% CI.

We then evaluated the association between immigrant status and health services utilization using negative binomial regression models, fitted via generalized estimating equations with an exchangeable correlation matrix to account for dependencies introduced by multiple measurements per individual. To account for partial residency time during a given year, we included the logarithm of person-time as an offset in all models. To identify yearly trends, an interaction term was included between immigrant status (yes or no) and the period (-1 to 2; i.e. --1 indicates 1 year before the diagnosis year) in all models. Rate ratios were adjusted for age at MS diagnosis, sex, income quintile, comorbidity burden (weighted ADG score), MS diagnosis calendar year, and urban/rural residence using the negative binomial regression models.

Model assumptions were tested using standard methods \[[@pone.0234876.ref024]\]. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

This study was approved by the research ethics boards at St. Michael's Hospital in Toronto, Ontario, Canada. Use of Ontario data in this study was authorized under section 45 of Ontario's Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system.

Results {#sec017}
=======

We identified 13,755 incident MS cases in Ontario from 2003--2014; 13,028 (94.7%) qualified for inclusion ([Fig 2](#pone.0234876.g002){ref-type="fig"}). Among the analytical sample, 1,070 (8.2%) were immigrants. Immigrants were slightly younger at diagnosis, had overall lower socioeconomic status as represented by neighbourhood income quintile, more often lived in urban areas, had lower mean comorbidity burden, and were more likely to enter the cohort in the later years of the study ([Table 1](#pone.0234876.t001){ref-type="table"}). More than 81% had been living in Canada for at least 5 years. There was no significant difference observed in sex distribution across the groups. The most highly represented regions of origin were Western countries (including Europe and North America) and the Middle East.

10.1371/journal.pone.0234876.t001

###### Baseline characteristics of cohort comparing immigrants versus long-term residents with MS.

![](pone.0234876.t001){#pone.0234876.t001g}

  Variable                                 Value                                    Immigrants N = 1,070   Long-term residents N = 11,958   Total N = 13,028   P-VALUE
  ---------------------------------------- ---------------------------------------- ---------------------- -------------------------------- ------------------ ---------
  **Diagnosis Year**                       2003                                     64 (6.0%)              987 (8.3%)                       1,051 (8.1%)       \<0.001
                                           2004                                     66 (6.2%)              1,022 (8.5%)                     1,088 (8.4%)       
                                           2005                                     71 (6.6%)              1,047 (8.8%)                     1,118 (8.6%)       
                                           2006                                     88 (8.2%)              984 (8.2%)                       1,072 (8.2%)       
                                           2007                                     84 (7.9%)              916 (7.7%)                       1,000 (7.7%)       
                                           2008                                     83 (7.8%)              957 (8.0%)                       1,040 (8.0%)       
                                           2009                                     103 (9.6%)             1,367 (11.4%)                    1,470 (11.3%)      
                                           2010                                     95 (8.9%)              1,296 (10.8%)                    1,391 (10.7%)      
                                           2011                                     94 (8.8%)              832 (7.0%)                       926 (7.1%)         
                                           2012                                     107 (10.0%)            862 (7.2%)                       969 (7.4%)         
                                           2013                                     109 (10.2%)            808 (6.8%)                       917 (7.0%)         
                                           2014                                     106 (9.9%)             880 (7.4%)                       986 (7.6%)         
  **Age at MS index, years**               Mean ± SD                                38.17 ± 10.56          39.72 ± 11.20                    39.59 ± 11.15      \<0.001
  **Age at MS Index, years (groups)**      20--35                                   452 (42.2%)            4,699 (39.3%)                    5,151 (39.5%)      \<0.001
                                           36--50                                   479 (44.8%)            4,970 (41.6%)                    5,449 (41.8%)      
                                           51--65                                   139 (13.0%)            2,289 (19.1%)                    2,428 (18.6%)      
  **Sex**                                  Female                                   742 (69.3%)            8,093 (67.7%)                    8,835 (67.8%)      0.263
                                           Male                                     328 (30.7%)            3,865 (32.3%)                    4,193 (32.2%)      
  **Neighbourhood income quintile**        1---lowest                               277 (25.9%)            2,241 (18.7%)                    2,518 (19.3%)      \<0.001
                                           2                                        184 (17.2%)            2,295 (19.2%)                    2,479 (19.0%)      
                                           3                                        214 (20.0%)            2,405 (20.1%)                    2,619 (20.1%)      
                                           4                                        244 (22.8%)            2,569 (21.5%)                    2,813 (21.6%)      
                                           5---highest                              150 (14.0%)            2,383 (19.9%)                    2,533 (19.4%)      
  **Rural residence**                      Urban                                    1,047 (97.9%)          10,372 (86.7%)                   11,419 (87.6%)     \<0.001
                                           Rural                                    23 (2.1%)              1,582 (13.2%)                    1,605 (12.3%)      
  **Weighted ADG score**                   Mean ± SD                                7.40 ± 11.63           8.42 ± 11.84                     8.34 ± 11.82       0.007
                                           Median (IQR)                             5 (1--14)              6 (1--16)                        6 (1--15)          0.007
  **Index year**                           2003--2004                               130 (12.1%)            2,009 (16.8%)                    2,139 (16.4%)      \<0.001
                                           2005--2009                               429 (40.1%)            5,271 (44.1%)                    5,700 (43.8%)      
                                           2010--2014                               511 (47.8%)            4,678 (39.1%)                    5,189 (39.8%)      
  **Reason for exit**                      Out migration/loss of OHIP eligibility   14 (1.3%)              137 (1.1%)                       151 (1.2%)         0.029
                                           Death                                    46 (4.3%)              755 (6.3%)                       801 (6.1%)         
                                           December 31, 2016                        1,010 (94.4%)          11,066 (92.5%)                   12,076 (92.7%)     
  **Follow-up years since MS diagnosis**   Mean ± SD                                7.17 ± 3.46            7.80 ± 3.47                      7.75 ± 3.48        \<0.001
  **Years since landing**                  Long Term Residents                      0 (0.0%)               11,958 (100.0%)                  11,958 (91.8%)     \<0.001
                                           within 2                                 36 (3.4%)              0 (0.0%)                         36 (0.3%)          
                                           2--5                                     165 (15.4%)            0 (0.0%)                         165 (1.3%)         
                                           5--10                                    269 (25.1%)            0 (0.0%)                         269 (2.1%)         
                                           10--15                                   228 (21.3%)            0 (0.0%)                         228 (1.8%)         
                                           15+                                      372 (34.8%)            0 (0.0%)                         372 (2.9%)         
  **Region of origin**                     Africa                                   46 (4.3%)              0 (0.0%)                         46 (0.4%)          
                                           Caribbean                                80 (7.5%)              0 (0.0%)                         80 (0.6%)          
                                           East Asia                                74 (6.9%)              0 (0.0%)                         74 (0.6%)          
                                           Hispanic America                         64 (6.0%)              0 (0.0%)                         64 (0.5%)          
                                           Middle East                              249 (23.3%)            0 (0.0%)                         249 (1.9%)         
                                           South Asia                               128 (12.0%)            0 (0.0%)                         128 (1.0%)         
                                           Western                                  392 (36.6%)            0 (0.0%)                         392 (3.0%)         

MS = multiple sclerosis.

ADG = Aggregated Diagnosis Groups.

Health service utilization analysis {#sec018}
-----------------------------------

### ED visits {#sec019}

Immigrants had lower rates of total ED use in the year before, the year of diagnosis and for the two post-diagnosis years ([Table 2](#pone.0234876.t002){ref-type="table"} and [Fig 3A](#pone.0234876.g003){ref-type="fig"}). Rates of MS-specific ED visits were similar in immigrants compared to long-term residents in the year of diagnosis and the two years post-diagnosis.

![Crude rates of health service utilization in immigrants vs. long-term residents with MS.\
Crude rates of health service utilization are shown for immigrants with MS compared to long-term residents with MS for (A) Emergency Department visits, (B) hospitalizations, and (C) outpatient neurology and primary care visits. For Emergency Department visits and hospitalizations, all event and MS-specific event rates are displayed.](pone.0234876.g003){#pone.0234876.g003}

10.1371/journal.pone.0234876.t002

###### Unadjusted and adjusted rate ratios comparing health services utilization in immigrants vs. long-term residents with multiple sclerosis.

![](pone.0234876.t002){#pone.0234876.t002g}

                                                                                           Unadjusted   Adjusted[\*](#t002fn001){ref-type="table-fn"}                                    
  --------------------------------------------------------- ------------------------------ ------------ ----------------------------------------------- ---------- ---------- ---------- ----------
  Total ED visits                                           1 year before diagnosis year   **0.59**     **0.52**                                        **0.67**   **0.66**   **0.58**   **0.74**
  Diagnosis year                                            **0.82**                       **0.73**     **0.91**                                        **0.86**   **0.78**   **0.96**   
  1st post diagnosis year                                   **0.61**                       **0.54**     **0.69**                                        **0.65**   **0.58**   **0.74**   
  2nd post diagnosis year                                   **0.68**                       **0.60**     **0.77**                                        **0.72**   **0.64**   **0.81**   
  ED visits for MS                                          Diagnosis year                 1.06         0.79                                            1.42       1.07       0.80       1.43
  1st post diagnosis year                                   0.82                           0.59         1.15                                            0.84       0.61       1.16       
  2nd post diagnosis year                                   0.84                           0.61         1.18                                            0.92       0.67       1.28       
  Total inpatient hospitalizations                          1 year before diagnosis year   **0.79**     **0.66**                                        **0.94**   0.86       0.73       1.01
  Diagnosis year                                            1.11                           0.95         1.29                                            **1.20**   **1.04**   **1.39**   
  1st post diagnosis year                                   **0.74**                       **0.62**     **0.88**                                        **0.79**   **0.67**   **0.94**   
  2nd post diagnosis year                                   0.87                           0.73         1.04                                            0.95       0.80       1.12       
  Inpatient hospitalizations for MS                         Diagnosis year                 **1.21**     **1.03**                                        **1.44**   **1.28**   **1.08**   **1.51**
  1st post diagnosis year                                   **0.73**                       **0.60**     **0.89**                                        **0.77**   **0.63**   **0.94**   
  2nd post diagnosis year                                   0.93                           0.75         1.14                                            0.97       0.79       1.19       
  Inpatient hospitalization length of stay (days)           1 year before diagnosis year   1.25         0.86                                            1.82       1.09       0.77       1.55
  Diagnosis year                                            1.15                           0.83         1.61                                            1.17       0.86       1.60       
  1st post diagnosis year                                   1.06                           0.73         1.54                                            1.28       0.91       1.82       
  2nd post diagnosis year                                   1.04                           0.72         1.51                                            1.08       0.76       1.53       
  Inpatient hospitalization for MS, length of stay (days)   Diagnosis year                 1.04         0.66                                            1.62       1.15       0.74       1.78
  1st post diagnosis year                                   1.42                           0.86         2.35                                            1.70       1.04       2.75       
  2nd post diagnosis year                                   1.21                           0.74         2.01                                            1.60       0.98       2.61       
  Total primary care outpatient visits                      1 year before diagnosis year   **0.81**     **0.74**                                        **0.88**   **0.88**   **0.82**   **0.95**
  Diagnosis year                                            **0.77**                       **0.71**     **0.82**                                        **0.84**   **0.78**   **0.90**   
  1st post diagnosis year                                   **0.69**                       **0.63**     **0.75**                                        **0.75**   **0.69**   **0.81**   
  2nd post diagnosis year                                   **0.71**                       **0.65**     **0.77**                                        **0.79**   **0.73**   **0.86**   
  Primary care outpatient visits for MS                     Diagnosis year                 **0.73**     **0.65**                                        **0.82**   **0.76**   **0.67**   **0.85**
  1st post diagnosis year                                   **0.79**                       **0.70**     **0.91**                                        **0.81**   **0.71**   **0.92**   
  2nd post diagnosis year                                   **0.85**                       **0.74**     **0.97**                                        **0.87**   **0.76**   **0.99**   
  Neurologist outpatient visits                             1 year before diagnosis year   0.95         0.89                                            1.01       **0.93**   **0.87**   **0.99**
  Diagnosis year                                            **1.19**                       **1.13**     **1.25**                                        **1.17**   **1.12**   **1.23**   
  1st post diagnosis year                                   **1.18**                       **1.12**     **1.25**                                        **1.16**   **1.10**   **1.23**   
  2nd post diagnosis year                                   **1.18**                       **1.11**     **1.24**                                        **1.16**   **1.09**   **1.22**   
  Total other specialist outpatient visits                  1 year before diagnosis year   **1.21**     **1.08**                                        **1.36**   **1.22**   **1.09**   **1.36**
  Diagnosis year                                            **1.22**                       **1.11**     **1.35**                                        **1.23**   **1.11**   **1.36**   
  1st post diagnosis year                                   **1.19**                       **1.06**     **1.33**                                        **1.19**   **1.06**   **1.33**   
  2nd post diagnosis year                                   1.07                           0.96         1.20                                            1.07       0.96       1.20       
  Other specialist outpatient visits for MS                 Diagnosis year                 1.08         0.81                                            1.46       1.15       0.85       1.55
  1st post diagnosis year                                   0.97                           0.70         1.36                                            1.06       0.76       1.48       
  2nd post diagnosis year                                   1.07                           0.77         1.50                                            1.18       0.85       1.64       

\*Rate ratios were adjusted for age at MS diagnosis, sex, neighbourhood income quintile, comorbidity burden (weighted ADG score), urban/rural residence, and MS diagnosis calendar year using negative binomial regression models.

95% CI = 95% Confidence Interval.

Bold face: statistically significant.

MS = multiple sclerosis.

ED = Emergency Department.

### Hospitalizations {#sec020}

Rates of hospitalization in immigrants were similar to long-term residents in the year before diagnosis ([Table 2](#pone.0234876.t002){ref-type="table"}). Immigrants had higher rates of both total and MS-specific hospitalizations in the MS diagnosis year ([Table 2](#pone.0234876.t002){ref-type="table"} and [Fig 3B](#pone.0234876.g003){ref-type="fig"}). In contrast, total and MS-specific hospitalizations were less frequent in immigrants in the first post-diagnosis year, but not significantly different from long-term residents in the second post-diagnosis year. Hospital length of stay (days) was longer in immigrants but this difference was not statistically significant.

### Primary care visits {#sec021}

Primary care visits, both total and MS-specific were less frequent in immigrants from the year before MS diagnosis through two years following diagnosis ([Table 2](#pone.0234876.t002){ref-type="table"} and [Fig 3C](#pone.0234876.g003){ref-type="fig"}).

### Neurology outpatient visits {#sec022}

Immigrants had lower rates of total neurology outpatient visits in the year before diagnosis, but higher rates of neurology specialty care in the year of MS diagnosis and for the two years post-diagnosis ([Table 2](#pone.0234876.t002){ref-type="table"} and [Fig 3C](#pone.0234876.g003){ref-type="fig"}).

### Other specialist outpatient visits {#sec023}

Other specialist outpatient visits were more likely among immigrants in the year before MS diagnosis, the year of diagnosis, and the first post-diagnosis year ([Table 2](#pone.0234876.t002){ref-type="table"}). In the second post diagnosis year, they continued to be more frequent in immigrants but this finding did not meet statistical significance. Similarly, MS-specific outpatient visits tended to be more common in immigrants in the year of MS diagnosis through two years following diagnosis but these observations were not statistically significant.

For most variables the regression analysis did not substantially alter the observed relationships. For the year of MS diagnosis, the relationship between immigrant status and total inpatient hospitalizations became statistically significant with adjustment for covariates; the relationship between immigrant status and MS-specific hospitalizations was statistically significant in both the adjusted and unadjusted analyses.

Discussion {#sec024}
==========

This novel study examined health services utilization in a large, population-based cohort of immigrants and long-term Ontario residents with MS. Immigrants demonstrated a higher rate of hospitalization in the year of MS diagnosis, despite greater use of neurology outpatient care. Other notable findings were a lower rate of primary care outpatient visits in immigrants and higher rates of other, non-neurology outpatient specialist visits. Overall, these findings suggest that immigrants with MS in Ontario, Canada, a region with universal health care insurance, are not systematically disadvantaged in their access to health services. Individuals with MS are expected to have higher rates of health services use compared to the general population, although many MS-related symptoms can be managed today on an outpatient basis \[[@pone.0234876.ref018],[@pone.0234876.ref025],[@pone.0234876.ref026]\]. In a previous scoping review of the literature, non-white race was associated with less access to health services in individuals with MS, although immigrant status was not investigated \[[@pone.0234876.ref009]\]. Studies of health service utilization may improve understanding of disparities across sociodemographic groups and in turn support policies to address those disparities.

However, despite the generally positive findings concerning access to health services in immigrants with MS in Ontario, the finding of a higher rate of hospitalization in the year of MS diagnosis is concerning, as higher use of outpatient neurology care is generally associated with fewer hospitalizations in neurologic diseases \[[@pone.0234876.ref006]\]. Possible explanations could include a more severe or sudden presentation of neurologic symptoms in immigrants with MS. More severe early demyelinating attacks and less neurologic recovery have been observed in individuals of non-white race in past research \[[@pone.0234876.ref027],[@pone.0234876.ref028]\]. We previously reported a higher risk of mortality in immigrants compared to long-term residents in the year following MS onset, although mortality in immigrants was lower thereafter \[[@pone.0234876.ref022]\]. Alternatively, immigrants may lack health system literacy and social supports which could mitigate the consequences of a first attack or other illness. However, a previous study found that economic class immigrants to Ontario had lower overall rates of hospitalization than the general population, possibly a reflection of the healthy migrant effect \[[@pone.0234876.ref029]\]. Immigrants to Ontario had lower rates of hospitalization for circulatory diseases in another study \[[@pone.0234876.ref030]\]. We did not observe higher rates of total or MS-specific hospitalization in immigrants outside of the MS-diagnosis year, which may argue against social supports playing a prominent role in the hospitalization patterns observed.

Lower rates of use of certain health services including outpatient neurology by immigrants in the year before MS diagnosis also raise the question of whether immigrants may have a shorter or less discernible MS prodrome, with more abrupt onset of demyelinating symptoms, compared to long-term residents in Canada. The MS prodrome refers to the onset of early symptoms that precede presentation with classic symptoms of the disease, as recognized by the observation that health service utilization increases steadily in individuals with MS relative to the general population beginning five years up until the time of MS diagnosis \[[@pone.0234876.ref026],[@pone.0234876.ref031]\]. Previously, a study of prodromal symptoms in women who later developed myocardial infarction found that race influenced the extent of prodromal symptoms, although the investigators did not assess immigrant status \[[@pone.0234876.ref032]\]. We also cannot exclude the possibility that immigrants experience similar symptoms before MS diagnosis as long-term residents but are less likely to seek out care because of financial, cultural, or language barriers and therefore may seek healthcare at later stages of the disease.

Strengths of this study include the availability of population-based continuous health services data, use of a validated algorithm for identifying MS cases \[[@pone.0234876.ref017]\], and the large cohort of immigrants and long-term residents with MS. We controlled for age, sex, socioeconomic status, urban/rural residence, overall comorbidity burden, and calendar year of diagnosis which may all contribute to disparities in health services use. Limitations of this study include lack of availability of prescription drug data which could have provided a more complete picture of access to needed health care resources among immigrants with MS. We cannot exclude the possibility of systematic differences in DMT prescriptions between immigrants and long-term residents but believe this is unlikely due to government coverage of DMT in Ontario for those without private drug insurance. The validated algorithm used to identify MS cases has a sensitivity of about 85%, and data concerning immigrants did not extend back before 1985, thus some MS cases may have been missed. We could not assess for differences in disability or disease severity between the immigrant and long-term resident populations because of lack of clinical data in the administrative health claims databases. Socioeconomic status was approximated by neighbourhood income quintile because individual-level variables such as household income are not collected as part of the health administrative data in Ontario. There may be some year-to-year stochastic variation in health service use. Last, this study focused on a region with universal health insurance with health services free at the point of care; health services use in immigrants with MS may differ under other insurance models and in other geographic regions.

Conclusions {#sec025}
===========

In conclusion, immigrants with MS in Ontario, Canada demonstrated a generally favourable pattern of access to health services, with greater use of neurology outpatient care and lower use of emergency department services. However, in the year of MS diagnosis immigrants had a higher rate of both total and MS-specific hospitalizations compared to long-term residents. Reasons for this are unclear but warrant further investigation and may include a more severe or abrupt presentation of neurologic symptoms of MS in immigrants.

10.1371/journal.pone.0234876.r001
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A second issue is that the authors do not discuss, in the introduction, what type(s) of utilization patterns would constitute a disparity indicative of worse MS care. This makes it difficult to understand how to interpret the results. Typically, in disparity research it is clearly stated what would constitute a disparity (e.g., lower rates of kidney transplantation, lower rates of having a certain drug prescribed). The authors should explicitly state this in the introduction, since many PLOS One readers will not be familiar with patterns of utilization associated with high quality care for MS, especially since they examine 5 types of care (hospitalizations, emergency department (ED) visits, outpatient neurology visits, other outpatient specialty visits, and primary care visits) at 3 different time points. It would be helpful to know how one should interpret the meaning of potential disparities for these 5 outcomes overall, and whether this meaning changes based on whether they occurred in the year before diagnosis, the year of diagnosis, and the two years following diagnosis. For example, are higher rates of neurological visits during the post-diagnosis period different, in terms of quality, than higher rates of neurological visits during the pre-diagnosis year? Perhaps a table could be helpful. In the conclusion, the authors state that their findings suggest that immigrants with MS in Ontario, demonstrated "a generally favourable pattern of access to health services with greater use of neurology outpatient care and lower use of emergency department services." Providing a description, in the introduction, of what a favorable pattern of health services utilization for MS consists of, would make it easier for the reader to interpret the results later and understand how the authors arrived at their conclusions. Along those lines, it would also be helpful to provide an example or examples of what one might learn from these analyses, in terms of how they might improve our understanding of disparities.

A third issue is the lack of a framework, in the introduction, systematically discussing factors that might contribute to disparities between immigrants and non-immigrants. The authors could draw on existing frameworks for presenting this information. This would provide a context for some of their findings that they discuss (such as to why immigrants experience a higher rate of hospitalization in the year of MS diagnosis despite higher use of outpatient neurology). A related point is that, when setting up their study in the introduction, the authors discuss research on racial/ethnic disparities and immigrant disparities without systematically discussing why these two groups' experiences might differ. It would strengthen the manuscript if the authors discussed specific factors that may contribute to different patterns of disparities in neurological care and MS care for immigrants compared to members of racial and ethnic minority groups.

Related to this, the authors should also be more explicit about why it is useful to focus on disparities within a system of universal health insurance. That is, within such a system, what other factors would be expected to contribute to disparities, for immigrants in general, and for their particular population in Ontario? Along those lines, when presenting their literature review, it would be useful to know whether any of the studies they cite were conducted in systems of universal health insurance.
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Dear Reviewers,

Thank you for your time, careful review, and thoughtful comments. Please see our responses below. We believe the manuscript has been strengthened with these changes and hope you find it suitable for publication.

Reviewer \#1:

1\. My main concerns focus on the framing of the manuscript, which right now lacks context and does not provide a sufficient framework for systematically understanding immigrant disparities in health services utilization for MS.

Response: We agree that the manuscript would benefit from more detailed framing at the outset and have revised the introduction extensively. Please see details below with respect to specific concerns.

2\. The first sentence in the introduction states that "disparity in health service utilization across sociodemographic groups is an important but poorly studied phenomenon which may influence health outcomes." This statement does not accurately characterize the disparities literature, as there have been many high-quality health services research studies documenting the presence and correlates of healthcare disparities in utilization across many disease conditions. The author should restructure the introduction to focus more narrowly on the specific gap in the literature that this study addresses: namely examining disparities in health services utilization for neurological diseases (MS, specifically) between immigrants and non-immigrants.

Response: Yes, this is an important point. There is a broader literature characterizing disparities in other disease states, which we now mention, then foreground the question regarding how disparities may affect MS care:

Health service access and utilization are known to vary substantially with sociodemographic factors such as sex, race, immigrant status, and income level (1-4). Disparities in health service utilization are reflected in divergent experiences of the health care system and outcomes (1, 5). However, health service utilization patterns have been less extensively described in the context of neurologic diseases, although one American study found that blacks were more likely to be hospitalized, and less likely to experience an ambulatory neurology visit, than whites (6). Health service utilization patterns may be particularly relevant for multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS) and one of the primary causes of disability in young adults (7). The complex treatment landscape for MS today requires specialized neurology care and early implementation of disease-modifying therapy (DMT) to promote better long-term outcomes (7, 8). Little is known about which sociodemographic factors predict favourable health service utilization in people living with multiple sclerosis (MS).

3\. A second issue is that the authors do not discuss, in the introduction, what type(s) of utilization patterns would constitute a disparity indicative of worse MS care. This makes it difficult to understand how to interpret the results. Typically, in disparity research it is clearly stated what would constitute a disparity (e.g., lower rates of kidney transplantation, lower rates of having a certain drug prescribed). The authors should explicitly state this in the introduction, since many PLOS One readers will not be familiar with patterns of utilization associated with high quality care for MS, especially since they examine 5 types of care (hospitalizations, emergency department (ED) visits, outpatient neurology visits, other outpatient specialty visits, and primary care visits) at 3 different time points. It would be helpful to know how one should interpret the meaning of potential disparities for these 5 outcomes overall, and whether this meaning changes based on whether they occurred in the year before diagnosis, the year of diagnosis, and the two years following diagnosis. For example, are higher rates of neurological visits during the post-diagnosis period different, in terms of quality, than higher rates of neurological visits during the pre-diagnosis year? Perhaps a table could be helpful. In the conclusion, the authors state that their findings suggest that immigrants with MS in Ontario, demonstrated "a generally favourable pattern of access to health services with greater use of neurology outpatient care and lower use of emergency department services." Providing a description, in the introduction, of what a favorable pattern of health services utilization for MS consists of, would make it easier for the reader to interpret the results later and understand how the authors arrived at their conclusions. Along those lines, it would also be helpful to provide an example or examples of what one might learn from these analyses, in terms of how they might improve our understanding of disparities.

Response: Thank you for this suggestion. We agree that it would be helpful to the reader to state in the introduction what constitutes a favourable pattern of health service use with respect to MS. We have added the following paragraph to the introduction:

A favourable pattern of health system utilization in those with established MS diagnoses would be characterized by regular outpatient neurology visits, as comprehensive MS care requires periodic monitoring of the patient's symptoms, neurologic examination, MRI, and response to DMT. Most MS attacks can be managed on an outpatient basis when there is consistent access to a neurologist; hence fewer emergency department visits and hospitalizations would be expected under favourable conditions (10). However, the initial symptoms or attack in MS may involve an emergency department visit to facilitate diagnostic work-up and possible treatment with corticosteroids (11). Hospitalization is usually required only for more severe attacks (10), the risk of which is reduced with DMT. Regular primary care visits may be appropriate if they complement rather than substitute for specialty neurology care and should be interpreted in that context (12).

4\. A third issue is the lack of a framework, in the introduction, systematically discussing factors that might contribute to disparities between immigrants and non-immigrants. The authors could draw on existing frameworks for presenting this information. This would provide a context for some of their findings that they discuss (such as to why immigrants experience a higher rate of hospitalization in the year of MS diagnosis despite higher use of outpatient neurology). A related point is that, when setting up their study in the introduction, the authors discuss research on racial/ethnic disparities and immigrant disparities without systematically discussing why these two groups' experiences might differ. It would strengthen the manuscript if the authors discussed specific factors that may contribute to different patterns of disparities in neurological care and MS care for immigrants compared to members of racial and ethnic minority groups.

Response: Thank you for this suggestion. We have added context to distinguish between the effects of race and immigrant status on health service utilization. We have added the following to the introduction:

There has been no previous study of the effect of immigrant status on health service utilization among people with MS, which is the focus of this study. The effect of immigrant status on health service utilization is distinct from the question of race, as health system literacy, language, and cultural factors affect immigrants' interaction with the health care system (13).

In the Discussion, we mention some other reasons why immigrants may have different patterns of health service use, including a lack of social supports and differences in the manner in which MS may present in different populations:

Possible explanations could include a more severe or sudden presentation of neurologic symptoms in immigrants with MS. More severe early demyelinating attacks and less neurologic recovery have been observed in individuals of non-white race in past research (27, 28). We previously reported a higher risk of mortality in immigrants compared to long-term residents in the year following MS onset, although mortality in immigrants was lower thereafter (22). Alternatively, immigrants may lack healthy system literacy and social supports which could mitigate the consequences of a first attack or other illness.

5\. Related to this, the authors should also be more explicit about why it is useful to focus on disparities within a system of universal health insurance. That is, within such a system, what other factors would be expected to contribute to disparities, for immigrants in general, and for their particular population in Ontario? Along those lines, when presenting their literature review, it would be useful to know whether any of the studies they cite were conducted in systems of universal health insurance.

Response: In the following excerpt from the introduction, we outline why it is important to study this question in a universal health insurance system (e.g. to remove the effect of differences in health insurance access in immigrant and non-immigrant population). In the section we mention above, we have added reference to other factors that contribute to disparities in immigrants, namely health system literacy, language, and cultural barriers, with a reference. We have added a reference to a previous study that compared health service utilization in a private health insurance system (the United States) vs. universal health insurance system (Canada) and found challenges for immigrants in both systems, although to a lesser extent in Canada's universal health insurance system:

We conducted this study in Ontario, Canada, a region that provides an ideal environment for isolating the effect of immigrant status beyond health coverage as it has one of the largest and most diverse immigrant populations globally (14); and because residents of Ontario have access to universal health insurance without user fees. In a previous large, community-based study, immigrants reported less favourable access to health services compared to native-born individuals in both Canada and the United States, although immigrants in Canada fared relatively better than their American counterparts (1).

Minor concern: The authors should replace the term "Caucasian" with white, as the term Caucasian has a problematic history. See Mukhopadhyay, C. C. (2016). Getting rid of the word\" Caucasian. Privilege: A Reader, 21.

Response: Thank you for this suggestion. We have replaced "Caucasian" with "white."

Reviewer \#2: The authors of the manuscript "Health service utilization in immigrants with multiple sclerosis" have written an interesting paper comparing the use of health services in immigrants to Ontario, Canada, compared to long-term residents.

The objectives are clearly defined, and the methods are fitted to answer the research questions. The pros and cons of the paper are mostly satisfactorily discussed. The health system in Canada ensures that the access to health services are universal and without user fees reducing this possible confounder to a minimum. There are however some issues that must be corrected and answered before the paper can be accepted.

1\. The socioeconomic status (SES) is roughly defined as the neighbourhood income quintile based on information from the Registered Persons Database of Ontario. SES could be more widely defined as the persons household income, education level, cultural aspects etc. Would it be possible to retrieve more detailed data on the individuals SES? If not, this should be mentioned in the discussion section.

Response: Thank you for this comment. As mentioned, neighbourhood income quintile was used as a proxy for SES, as has been done in other studies (Tu et al. 2015, in Reference List). Unfortunately it is not possible to derive person-specific socioeconomic measures with the linked administrative health data available for our study. We have added this as a limitation in the Discussion:

Socioeconomic status was approximated by neighbourhood income quintile because individual-level variables such as household income are not collected as part of the health administrative data in Ontario.

2\. The immigrants were identified by electronic IRCC data which captures those arriving in Ontario since 1985. Thus people arriving to Canada from foreign countries before 1985 and later developing MS, would be defined as "long-term residents." The authors should discuss this issue and eventually how this might affect the results.

Response: It is a potential limitation that the data concerning immigrants did not extend back before 1985. However, we do not expect to have missed many cases of MS in immigrants during our study period from 2003-2014 given that the usual age of MS onset is in young adulthood. The same approach has been taken in other studies (Yarnell et al. JAMA 2017, Tu et al. Circulation 2015). We have added mention of this limitation to the Discussion.

3\. The first sentence under "Results" refers to Figure 1. This should be corrected to Figure 2.

Response: Thank you -- this has been corrected.

4\. In figure 3, crude rates are given for the health service utilization in immigrants vs. long-term residents, whereas both crude rates and adjusted rates are given in table 2. It should be more clear how the results were affected by these adjustments and if this would alter the conclusions.

Response: The results were not substantially altered by the regression analysis with one notable exception. We have added the following to the end of the Results section:

For most variables the regression analysis did not substantially change the observed relationships. For the year of MS diagnosis, the relationship between immigrant status and total inpatient hospitalizations became statistically significant with adjustment for covariates; the relationship between immigrant status and MS-specific hospitalizations was statistically significant in both the adjusted and unadjusted analyses.

5\. As the authors mention in the Discussion section, information about prescription of MS drugs is lacking. Different drugs have different side effect and complication rates, including severe reactions that could require hospital admissions. Could possible systematically differences in the prescription of MS drugs between the ethnic groups explain some of the skewness between outpatient visits and hospitalizations?

Response: Thank you for this interesting comment. We do not have the data to exclude whether there could have been a systematic difference in prescriptions across the immigrant versus long-term resident population. We have added mention of this as a limitation to the Discussion. However, disease modifying therapies are covered by the government (Exceptional Access Program) in Ontario for those without private drug insurance. Therefore, given coverage and the access patterns to outpatient neurology observed in this study we think that it is unlikely that there would have been a major difference in prescription patterns across groups. Furthermore serious adverse events requiring hospitalization on MS drugs are quite rare.
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